Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
Saudi Pharm J
; 28(11): 1333-1352, 2020 Nov.
Article
em En
| MEDLINE
| ID: mdl-32905015
ACE2, angiotensin-converting enzyme 2; AHFS, American Hospital Formula Service; ANGII, angiotensin II; APCs, antigen presenting cells; ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease; CoVs, coronaviruses; Coronavirus; GVHD, graft versus host disease; HCoVs, human coronoaviruses; IBV, infectious bronchitis coronavirus; IFN-γ, interferon-gamma; ILCs, innate lymphoid cells; Investigational medications; MERS-CoV, Middle East respiratory syndrome; NKs, natural killer cells; ORFs, open reading frames; PAMPs, pathogen-associated molecular patterns; Pandemic; Pathophysiology; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SLE, systemic lupus erythematosus; TMPRSS2, transmembrane serine protease 2; Viral immune response; WHO, World Health Organization; nsps, nonstructural proteins
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article